65,437 trials
Myotonic Dystrophy Type 1
Primary: Change From Baseline to Week 24 in Distance Walked as Assessed by the Six-minute Walk Test (6MWT) Distance — 12.40; 20.11 meters
Wet Macular Degeneration
Primary: Area of Lesion Measured by Optical Coherence Tomography Angiography (OCTA) Scan. — 1.07 mm^2
Carcinoma, Non-Small-Cell Lung
Primary: Time to Death or Distant Metastasis — 30.7 months
Human Immunodeficiency Virus (HIV)
Primary: Incidence of Treatment-Emergent Adverse Events — 0; 0; 0; 0 Participants
Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7 · Stage II Prostate Adenocarcinoma AJCC v7 · Stage III Prostate Adenocarcinoma AJCC v7
Primary: Number of Participants Who Completed the Maximum Time Allowed on Study Without Severe Acute Surgical Complications — 11 Participants
Gonorrhea of Pharynx · Gonorrhea
Primary: Treatment Efficacy of Pharyngeal Gonorrhea as Defined as the Proportion of Study Participants With Positive Pharyngeal Gonorrhea Culture at of Enrollment Whose Test of…
Tricuspid Valve Regurgitation
Primary: Major Adverse Event Rate : Count and Percentage of Patients Who Experienced at Least One MAE — 10 Participants
Palmoplantaris Pustulosis
Primary: Percentage of Participants Who Achieve a PPPASI-50 at Week 16 — 40.9; 78.3 Percentage of Partcipants — p=0.0003
COVID-19
Primary: Time to Alleviation of COVID-19-related Symptoms by Day 30 — 19.0; 19.0 days
Kidney Transplantation · Primary Focal Segmental Glomerulosclerosis (FSGS)
Primary: Percentage of Participants With Recurrence of Focal Segmental Glomerulosclerosis (rFSGS) or Death or Graft Loss or Lost to Follow-up Through 3 Months Post Transplant…
Diabetes Mellitus
Primary: Fingerstick Contour Next BGMS and Contour TV3 Results Compared to the Reference Analyzer — 366; 360 Participants
Treatment of Chronic Obstructive Pulmonary Disease
Primary: Percentage of Patients With Discontinued or Expired and Not Renewed Inhaled Corticosteroids That Remain Off at 6 Months. — 94; 174 Participants — p=<0.001
Gastroparesis
Primary: Change From Baseline (Day 1) in Maximal Tolerated Volume Consumed During the Nutrient Satiety Test at Day 14 — 293.5; 345.6; 1.3; 2.0 mL — p=0.9030
Postural Tachycardia Syndrome (POTS)
Primary: FMD (% Change) — 12.75; 11.65; 11.43; 12.75 percentage of change
Kidney Cancer
Primary: Number of Patients With Adverse Events (AEs) — 3; 8; 3 Participants